FTSE MIB
34.646,92 +307,60 (+0,90%) Dow Jones
39.494,84 +107,08 (+0,27%) Nasdaq
16.340,70 -5,56 (-0,03%) Nikkei 225
38.229,11 +155,13 (+0,41%) Petrolio
79,43 +0,17 (+0,21%) Bitcoin EUR
57.214,08 +128,37 (+0,22%)
Arvinas, Inc. (ARVN)
| Chiusura precedente | 31,95 |
| Aperto | 32,21 |
| Denaro | 22,96 x 200 |
| Lettera | 40,65 x 200 |
| Min-Max giorno | 31,51 - 32,42 |
| Intervallo di 52 settimane | 13,57 - 53,08 |
| Volume | |
| Media Volume | 734.664 |
| Capitalizzazione | 2,182B |
| Beta (5 anni mensile) | 1,95 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -6,05 |
| Prossima data utili | 06 ago 2024 - 12 ago 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 68,78 |
GlobeNewswireArvinas Announces Upcoming Bavdegalutamide Poster Presentation at ESMO Congress 2023
NEW HAVEN, Conn., Oct. 15, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced it will present updated Phase 1/2 trial data for bavdegalutamide (ARV-110) at the 2023 European Society for Medical Oncology (ESMO) Annual Congress. Bavdegalutamide is an investigational orally bioavailable PROTAC® androgen receptor (AR) degrader and is being developed as a potential treatment
- GlobeNewswire
Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation at ESMO Congress 2023
NEW HAVEN, Conn. and NEW YORK, Oct. 15, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced they will present updated Phase 1/2 data for vepdegestrant (ARV-471) at the 2023 European Society for Medical Oncology (ESMO) Annual Congress. Vepdegestrant is a novel oral PROTAC® estrogen receptor (ER) degrader that is being jointly developed by Arvinas and Pfizer for the treatment of patients with locally advanced or metastatic ER positive/human epidermal g
- GlobeNewswire
Arvinas to Participate in Upcoming Investor Conferences
NEW HAVEN, Conn., Sept. 01, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in three upcoming investor conferences: Wells Fargo 2023 Healthcare Conference on Wednesday, September 6. Ron Peck, M.D., Chief Medical Officer, and Sean Cassidy, Chief Financial Officer, will participate in a fireside chat. A live audio webcast of the present
